APSR2026-232

 
Late-Breaking
Submitted
Poster Presentation
 
AP06-018
P18
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1213446-46904-UITM EGPA VS AEP APSR SYAHRIN_439471.pdf
Format: PDF Only
01. Clinical Respiratory Medicine
6

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Syahrinnaquiah Samsuddin * University Technology MARA, Sungai Buloh Department of Medicine Selangor Malaysia
Am Basheeri Alias - University Technology MARA, Sungai Buloh Department of Medicine Selangor Malaysia
Yen Shen Wong - University Technology MARA, Sungai Buloh Department of Medicine Selangor Malaysia
Aisya Natasya Musa - University Technology MARA, Sungai Buloh Department of Medicine Selangor Malaysia
Roqiah Fatmawati Abdul Kadir - University Technology MARA, Sungai Buloh Department of Radiology Selangor Malaysia
Nor Salmah Bakar - University Technology MARA, Sungai Buloh Department of Pathology Selangor Malaysia
 
 
 
 
 
 
 
 
 
Presenting Author Details
Syahrinnaquiah
Samsuddin
syahrin.samsuddin@gmail.com
+60193884887
31-40
Malaysia
Case Report
When Eosinophilia Clouds the Picture: Acute Eosinophilic Pneumonia (AEP) versus Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Maximum 25 words
Abstract Content
 
 
 
 
Distinguishing acute eosinophilic pneumonia (AEP) from eosinophilic granulomatosis with polyangiitis (EGPA) can be challenging, particularly in critically ill patients with respiratory failure and eosinophilia. Importantly, antineutrophil cytoplasmic antibody (ANCA) negativity does not exclude EGPA. Systemic corticosteroids remain the mainstay of treatment, while anti–interleukin-5 (anti–IL-5) therapy has emerged as a useful adjunct, especially in refractory or relapsing disease.
A 38-year-old gentleman with a 7-year history of asthma on inhaled corticosteroid/long-acting beta-agonist therapy presented with fever and worsening dyspnea. He had no history of nasal polyps, renal impairment, or hematuria. He developed acute respiratory distress syndrome (ARDS) requiring intensive care unit admission and mechanical ventilation. Laboratory tests showed elevated inflammatory markers and persistent peripheral eosinophilia. Bronchoscopy with bronchoalveolar lavage (BAL) isolated Pseudomonas aeruginosa, and targeted antibiotic therapy was started. Despite adequate antimicrobial treatment, clinical improvement was insignificant. A repeat bronchoscopy with differential cell count demonstrated eosinophilic predominance. Systemic corticosteroids were initiated, resulting in a partial response. A stat dose of anti–IL-5 therapy was administered; subsequently, the patient showed marked clinical improvement, allowing successful extubation and oxygen weaning. Autoimmune screening, including ANCA, was negative. A provisional diagnosis of acute eosinophilic pneumonia was made. However, during steroid tapering, recurrent eosinophilia occurred. Reassessment using the 2022 American College of Rheumatology (ACR) classification criteria fulfilled a diagnosis of EGPA. Anti–IL-5 therapy was continued, and steroids were successfully tapered.
Initial diagnosis of AEP was initially favored, relapse of eosinophilia during steroid tapering, and fulfillment of updated ACR 2022 criteria supported a diagnosis of EGPA despite ANCA negativity. This highlights that ANCA-negative EGPA remains a recognized phenotype, often presented with predominant respiratory manifestations. Anti–IL-5 therapy played a crucial role in disease control, facilitating steroid reduction and clinical recovery.
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Acute eosinophilic pneumonia, Eosinophiic granulomatosis with polyangiitis, eosinophilia
maximum 3 keywords and no abbreviations, separated by commas
Nothing to disclose
286